The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Interested to hear what they have to say. I’m calling zero sales.
Yes mate.
The Delta virus is going to be allowed to circulate freely. Everyone will have it or will have had it. Mass testing is only required with low virus prevalence. Kids and NHS will still test. Test needed to be out last year. There isn’t a company in the UK that will sell anywhere near the amount Innova have. Not unless a new variant appears.
Very tempted to buy here at the bottom of the PRZ. Two things stopping me. It’s being beaten down by the shorts and next week that idiot Colin King is going to announce near zero sales into the UK and EU.
This won’t be taken over until the chemo drug is shown to work. As Al himself has already said, if companies want to be taken over, they need to hit major milestones first. 2023/24.
Are you for real. Boris was talking last NOVEMBER. Most probably about the Mologic or Avacta test, both of which subsequently failed at Porton Down. He then switched to Plan B and took billions of Chinese tests. The new NHS test is the Chinese Orient Gene test. Surescreen will get a few orders. Neither need ODX. It is literally staring you right in the face and has been for months now but confirmation bias has gripped these COVID shares. Don’t take it from me, take it from Colin next week.
Your average punter on the street won’t care about a few percent difference in the sens and spec. They won’t even know. “Can I have the cheapest one that’s government approved please”. Chinese will undercut everyone on price. It’s concerning they’re obviously offering the agent a bigger margin to push the sales.
@SheerClass - Nailed it. I don’t expect anyone here to be selling at these prices, not when you could have done so over 250p ( and I won’t be but I’m on a free run) although I fully expect be buying back at 120p and below. Easily reached if 141p doesn’t hold.
The Delta variant is going to be allowed to circulate freely amongst the population. Once the end of September comes and only the kids are left unvaccinated there will be no requirement for testing. Everyone will have the Delta variant anyway and testing is only ever required with low prevalence. It’s ripping through Newcastle right now. The rest of the country will follow. The same will happen in the EU and USA. The test needed to be out before winter last year. Excellent opportunity to buy more over the coming weeks. Like it or not, the market is going to factor in zero sales until proven otherwise.
New Gov requirements now have saliva as the preferred method. Saliva along with a high specificity. Specificity must be >99.5% min and Sensitivity >80% min for the rule in test. The one that will take the bulk of the orders. Given that the new NCYT saliva test only failed by 0.2% specificity, are there any other saliva tests out there? Has Al been working on the AVCT saliva test in the background now the gov have flip flopped on him again. Surely it would hit 99.5% spec and 80% sensitivity. The sensitivity requirements were a lot higher last year when it failed. Government is talking about a new TYPE of test for schools. Parents don’t want swabs. Education secretary about to announce a new way out of isolation for kids. https://www.gov.uk/government/publications/how-tests-and-testing-kits-for-coronavirus-covid-19-work/target-product-profile-in-vitro-diagnostic-ivd-self-tests-for-the-detection-of-sars-cov-2-in-people-without-symptoms
I must have missed the RNS where the test passed PD. Chemo looks awesome though. 5 to 10% royalties for years to come if it works.
In March it was the absolute intention of the gov to use Mologic and ODX. See Jim Bethells tweet from that month. It’s July tomorrow. The Mologic test failed at PD. Innova were awarded a 4 billion pound contract and things changed. Unfortunately no one told the investors but the SP went from 109p to 53p giving a clear indication that some smart ones had figured it out.
Completely wrong. The latest gov requirements for self test devices have saliva as desired and swab as acceptable. They also only require a high specificity for the rule in test. Sensitivity isn’t important for the rule in test. Nova tick both boxes.
Incorrect by some on here to state swabs are the preferred method. Swabs have been downgraded to merely acceptable in the latest gov requirements for self testing. Methods that DO NOT use swabs are now classed as the preferred method. Understandable given the low uptake by members of the public.
The recruitment is a bit of a bull trap for me. Essentially, the gov have provided machines to ODX and are also paying them to have trained staff on stand by, should they be needed, up to Feb 2023. There is a min value in the contract. It is absolutely nothing to the gov. For a tiny amount they get a plan B on standby. Smart money is waiting to see if the gov actually use ODX and as Colin said, even if they do, it could be way less than £374 million. They’re 4 months into the contract now.
You want to go against the sharks on AIM, you need to put your dreams to one side and start selling. 50% up, sell a few, 100% up, get your stake out. It will drop big time. It always does. It doesn’t matter what you think the fundamentals are; AIM companies don’t have them. AIM CEOs are never to be trusted. AIM RNSs are always an opportunity to sell, no matter how awesome they seem. This was an easy sell above 250p and it’s an easy buy now. Don’t treat these loss making dogs like they’re special.
You do realise MHRA have no issues with Innova. Business as usual.
You do realise Innova are building a factory in Wales?
Innova can carry on selling forever.
Producers of tests currently on the market will need to apply for validation by 1st September 2021 and have passed successfully by 31 October 2021 in order to continue selling tests past 31 October 2021. Tests currently supplied to the NHS under DHSC procurement will be exempted in recognition of prior equivalent assessment.